Lecithin-based nanocapsule loading sucupira (Pterodon emarginatus) oil effects in experimental mucositis.

dc.contributor.authorDi Miceli, Jeruza Ferraz Filgueiras
dc.contributor.authorAndrade, Maria Emília Rabelo
dc.contributor.authorCarvalho, Paula Lopes Armond
dc.contributor.authorSantos, Elandia Aparecida
dc.contributor.authorOliveira, Anna Eliza Maciel de Faria Mota
dc.contributor.authorFernandes, Caio Pinho
dc.contributor.authorCruz, Rodrigo Alves Soares
dc.contributor.authorGarrett, Rafael
dc.contributor.authorMosqueira, Vanessa Carla Furtado
dc.contributor.authorCassali, Geovanni Dantas
dc.contributor.authorD’Haese, Cecile
dc.contributor.authorNysten, Bernard
dc.contributor.authorLeite, Jacqueline Isaura Alvarez
dc.contributor.authorCardoso, Valbert Nascimento
dc.contributor.authorAraújo, Raquel Silva
dc.date.accessioned2023-10-17T20:21:20Z
dc.date.available2023-10-17T20:21:20Z
dc.date.issued2022pt_BR
dc.description.abstractIntestinal mucositis (IM) is a frequent adverse effect in anticancer therapy without standard treatment. The oil obtained from sucupira (Pterodon emarginatus) has anti-inflammatory properties, and the soybean lecithin re- duces the intestinal toxicity of several xenobiotics. However, their water insolubility impairs the in vivo appli- cation. For this reason, we evaluated if the nanoencapsulation of sucupira oil (SO) in lecithin-based nanocapsules (SO-NC) could be a therapeutically effective system for the treatment of IM in murine cisplatin (CDDP)-induced intestinal mucositis model. SO was analyzed by LC-HRMS/MS and HPLC. SO-NC was prepared by nano- precipitation and characterized using DLS, HPLC, and AFM. Mice body weight and food consumption were assessed daily during experimental mucositis induced by CDDP. The animals were euthanized, and intestinal permeability, inflammatory mediators, and intestinal histology were performed. SO-NC demonstrated adequate characteristics for oral administration as size under 300 nm, IP < 0.3, high EE, and spherical shape. In vitro cytotoxicity performed against RAW 264.7 cell lines resulted in cell viability above 80 % confirming the non- cytotoxic profile of SO (IC50 268 μg/mL) and SO-NC (IC50 118.5 μg/mL) up to 117.2 μg/mL. The untreated mice showed intestinal toxicity after i.p. of CDDP, principally weight loss, increased intestinal permeability, and MPO and TNF-α levels. Surprisingly, the administration of SO to CDDP-mucositis animals did not circumvent the CDDP effects and increased intestinal permeability. However, SO-NC proved efficient in mitigating the experi- mental intestinal mucositis by improving intestinal epithelium architecture, reducing intestinal permeability, and improving the MPO levels. In conclusion, SO-NC can positively impact intestinal mucositis by promoting mucosal recovery. This is a promising strategy for developing a new treatment for intestinal mucositis.pt_BR
dc.identifier.citationDI MICELI, J. F. F. et al. Lecithin-based nanocapsule loading sucupira (Pterodon emarginatus) oil effects in experimental mucositis. Toxicology Reports, v. 9, p. 1537–1547, 2022. Disponível em: <https://www.sciencedirect.com/science/article/pii/S2214750022001603>. Acesso em: 01 ago. 2023.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.toxrep.2022.07.006pt_BR
dc.identifier.issn2214-7500
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/17587
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/). Fonte: PDF do artigo.pt_BR
dc.subjectIntestinal permeabilitypt_BR
dc.titleLecithin-based nanocapsule loading sucupira (Pterodon emarginatus) oil effects in experimental mucositis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
ARTIGO_LecithinBasedNanocapsule.pdf
Tamanho:
4.94 MB
Formato:
Adobe Portable Document Format
Descrição:
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: